Berkshire Hathaway Under Greg Abel Balancing Oxychem Deal And Cash Choices

Berkshire Hathaway Inc. Class B -0.24%

Berkshire Hathaway Inc. Class B

BRK.B

477.35

-0.24%

  • Warren Buffett has stepped back from the CEO role at Berkshire Hathaway (NYSE:BRK.B), and Greg Abel is now leading the company.
  • Abel’s early decisions include the large Oxychem acquisition and continued reductions in major equity holdings such as Apple and Bank of America.
  • Berkshire Hathaway is holding a sizable cash balance while adjusting its capital allocation approach under new leadership.

Berkshire Hathaway, known for its mix of insurance, energy, rail, industrial and consumer businesses, is entering a new chapter under Greg Abel. The Oxychem deal and portfolio changes give investors fresh data points on how Abel is steering a company long associated with Warren Buffett’s investment style.

As capital deployment shifts, investors in NYSE:BRK.B are watching how cash levels, acquisitions and share repurchases fit together under the new playbook. The focus now is less on individual stock picks and more on how the overall capital pool is being managed across businesses, securities and cash.

Stay updated on the most important news stories for Berkshire Hathaway by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Berkshire Hathaway.

NYSE:BRK.B Earnings & Revenue Growth as at Mar 2026
NYSE:BRK.B Earnings & Revenue Growth as at Mar 2026

Quick Assessment

  • ⚖️ Price vs Analyst Target: At US$468.49, Berkshire Hathaway trades about 8% below the US$507.21 analyst target, which sits within the one standard deviation range of US$463.70 to US$550.72.
  • ✅ Simply Wall St Valuation: Simply Wall St currently assesses the shares as trading about 41.4% below its estimated fair value, flagged as undervalued.
  • ❌ Recent Momentum: The 30 day return of about 5.2% decline shows recent sentiment has been weak despite the valuation signals.

There is only one way to know the right time to buy, sell or hold Berkshire Hathaway. Head to the Simply Wall St company report for the latest analysis of Berkshire Hathaway's Fair Value.

Key Considerations

  • 📊 Leadership transition to Greg Abel, the Oxychem acquisition and portfolio shifts indicate that capital allocation decisions may look different to the Buffett era. It is worth reassessing how this fits your expectations.
  • 📊 Watch how the large cash balance, future deal activity, share repurchases and the current P/E of about 15.1 relative to the 17.0 fair ratio evolve against the analyst target range of US$462.70 to US$576.83.
  • ⚠️ Forecasts pointing to an average 4.8% annual earnings decline over the next 3 years sit against the undervaluation case and are a key input to stress test before making any decision.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Berkshire Hathaway analysis. Alternatively, you can visit the community page for Berkshire Hathaway to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.